Spain Anti-Rheumatic Drug Market Size, Share, Opportunities, And Trends By Type Of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Drug Class (Disease-modifying Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, JAK Inhibitor, Others), And By Sales Channel (Prescription, Over-the-counter (OTC)) - Forecasts From 2023 To 2028

The Spain antirheumatic drug market is expected to grow at a compound annual growth rate of 2.12% over the forecast period to reach a market size of US$4,011.904 million in 2028, from US$3,463.331 million in 2021.

Anti-rheumatic drugs are substances that are administered to treat rheumatoid arthritis, among other diseases like gout, lupus, osteoarthritis, and so on. The market in the region is expected to see growth due to the growing geriatric population along with the presence of a fair share of pharmaceutical companies in the region.

Growth factors:

The anti-rheumatic drugs market in Spain is expected to be considerably driven due to the prevalence of rheumatic diseases in the region.

Rise in rheumatoid arthritis in Spain is expected to drive the market growth of the anti-rheumatic drug market. Rheumatoid arthritis is considered one of the most common types of autoimmune arthritis. It is a chronic inflammatory disorder that not only affects the joints but is also capable of damaging a wide variety of body systems. According to a study published in the Journal of Rheumatology, the prevalence of rheumatic diseases in Spain is around 18.9%, which is higher than the European average.

The rising old-age population in the country is expected to be one of the key factors contributing to the market growth in the region.

Over the past few years, there has been an increase in the geriatric population of Spain. The rising aging population is boosting the demand for these drugs as the demographic shift towards an older population is putting a higher burden on various age-associated diseases worldwide. Factors such as increased life expectancy and declining fertility are the key factors behind the growing aging population. As per the United Nations Population Division, the geriatric population in Spain, 65 years of age or older, grew from a population size of 9,31 8,013 to 9,437,101 from 2020 to 2021. Since aged people are the most susceptible to suffering from these diseases, the demand for rheumatic drugs is growing significantly, thus positively impacting the growth of the anti-rheumatic drug market.

Key development:

• In January 2023, the DSI (Department of Science and Innovation) and IPASA (Innovative Pharmaceutical Association of South Spain) collaborated with the SAMRC (South Spainn Medical Research Council) in order to enhance the R&D capability in South Spain along with the commercialization of novel and innovative health solutions and boosting the pharmaceutical sector in the country. The IPASA is an association that consists of key market players like Merck, Novartis, Pfizer, and Roche, to name a few.
• Pfizer Nigeria launched a patient assistance program, “Project Afya” in 2019 which focuses on improving access to life-saving medication and treatment of rheumatoid arthritis for people living in rural and low-income areas.

Anti-rheumatic drugs are medications that are used in the treatment of autoimmune conditions such as rheumatoid arthritis, and psoriatic arthritis for decreasing inflammation, and pain and preventing joint damage Besides rheumatoid arthritis, anti-rheumatic drugs are further used in the treatment of other autoimmune diseases such as lupus where the immune system attacks the healthier cells and organs of the body, thereby causing inflammation in joints, kidneys, heart, and lungs.

Substantial investment by Spain towards drugs and healthcare is thus expected to drive growth for DMARDs as well.

Based on drug class, the Spain anti-rheumatic drug market is segmented into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, JAK inhibitors, and others. DMARDs are used for the treatment of chronic diseases like rheumatoid arthritis and psoriatic arthritis. These types of anti-rheumatic drugs target the underlying clinical condition instead of targeting the actual symptoms. Adding to this, the vast investments by healthcare companies in drugs are expected to further boost the market growth. According to data published by the Ministry of Health of Spain, in December 2022, EUR 90.3 billion was allocated towards public health with EUR 12.8 billion out of that allocated towards prescription drugs.

Spain Anti-Rheumatic Drug Market Scope:

Market Segmentation:

• By Type Of Disease
  • Osteoarthritis
  • Rheumatoid Arthritis
  • Gout
  • Lupus
  • Others
• By Drug Class
  • Disease-modifying Anti-Rheumatic Drugs (DMARDs)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • JAK inhibitor
  • Others
• By Sales Channel
  • Prescription
  • Over-the-counter (OTC)

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. SPAIN ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY TYPE OF DISEASE

5.1. Introduction

5.2. Osteoarthritis

5.3. Rheumatoid Arthritis

5.4. Gout

5.5. Lupus

5.6. Others

6. SPAIN ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY DRUG CLASS

6.1. Introduction

6.2. Disease-modifying Anti-Rheumatic Drugs (DMARDs)

6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

6.4. Corticosteroids

6.5. JAK inhibitor

6.6. Others

7. SPAIN ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY SALES CHANNEL

7.1. Introduction

7.2. Prescription

7.3. Over-The-Counter (OTC)

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES 

9.1. AbbVie Inc.

9.2. Amget Inc. 

9.3. Johnson and Johnson

9.4. Pfizer Inc.

9.5. GlaxoSmithKline plc

9.6. Merck & Co., Inc.

9.7. Eli Lilly and Company

9.8. Novartis AG

9.9. Celgene Corporation (Bristol-Myers Squibb)

AbbVie Inc.

Amget Inc.

Johnson and Johnson

Pfizer Inc.

GlaxoSmithKline plc

Merck & Co., Inc.

Eli Lilly and Company

Novartis AG

Celgene Corporation (Bristol-Myers Squibb)